Back to Investors
VC

Ventura Capital

Venture Capital

Ventura Capital invests in consumer technology disruptors.

Portfolio

6

companies


Portfolio companies

Owlstone Medical

Owlstone Medical

Owlstone Medical provides breath biopsy technology for early disease detection and precision medicine.

Plum

Plum

Plum provides a smart money application that helps users automate savings and investments.

Zilch

Zilch

Zilch provides an alternative payment platform combining debit and credit features with cash flow management.

D

DnaNudge

DnaNudge provides consumer genetics testing and rapid medical diagnostics.

I

Invstr

Invstr operates a social investment application providing retail traders with educational tools and brokerage services.

Railsbank

Railsbank

Railsbank provides an embedded finance platform that lets companies build custom financial products.


Team

ME

Mo El Husseiny

Founder and Managing Partner

Mo brings investment and acquisitions experience from Goldman Sachs, Mubadala, and Ventura Capital. He also serves as vice chairman of Royal Albert Hall America.

LinkedIn

Recent investments

Series D+
£22.0M

Ventura Capital led the Series E round, with participation from Aviva Ventures, Horizons Ventures, and the Gates Foundation, to advance clinical trials and commercialise breath tests.

"Testament to the power of Breath Biopsy is the continued strong support we continue to enjoy from our investors. The funds closed will enable us to progress our business to the next stage, advancing clinical trials and supporting the launch and commercialization of our pipeline of unique breath tests."
— Billy Boyle, co-founder and CEO
Series B
£16.0M

The funding round was backed by institutional investors including Eurobank and iGrow Venture Capital, alongside a crowd-funding campaign.

"It has been an exceptional 12 months for Plum, and this new round of funding is testament to the hard work of the team and the value we’re providing for customers across Europe. The need for a smart app that helps people grow their money for life has never been stronger, and we’re already delivering this to millions of people."
— Victor Trokoudes, Founder and CEO
Series C
£82.0M

The funding round was led by Ventura Capital and Gauss Ventures, with participation from Goldman Sachs, pushing the company valuation to $2bn.

"It’s really been phenomenal to watch customers adopt our product at such significant speed. Our entire 200+ team is truly humbled and grateful for the opportunity to serve millions of customers daily and rest assured we are all working around the clock to delight them. We have been fortunate to experience such phenomenal growth over the last 14 months and today we are celebrating becoming one of Europe’s fastest unicorns.Our unique business model, which is built on regulation and places consumer financial wellness at the heart of our operations, has created a revolution in the BNPL industry. We’re excited about this major milestone but realise that the job is nowhere near done and this really only marks the beginning of our growth journey as we aim to become the best way for consumers to pay for anything, anywhere."
— Philip Belamant, CEO & Co-Founder
Series A
£10.4M

The financing round was led by dmg ventures and Ventura Capital to support international growth and asset expansion.

"Wealth for all is our mission and we’ve made some great strides towards making that reality this year, expanding our user base massively and delivering a product that looks more-and-more like a financial super app. But there’s a lot more work to be done. The appetite for smart and intuitive investment products is enormous, particularly in other parts of Europe where often old-fashioned banks are the only option for growing your money. With the help of this new investment and our upcoming crowdfund, our app will become the natural choice for anyone in Europe looking to improve their finances for the long-term."
— Victor Trokoudes, Founder and CEO
Series A
£43.6M

The investment round was led by Ventura Capital and will accelerate international deployment of the company's diagnostic platform.

"The game-changing nature of our innovation has created an extraordinary commercial opportunity within next-generation medical diagnostics, and the global investor community is very excited by the transformative potential of a rapid, gold-standard RT-PCR testing platform that can screen for multiple viruses simultaneously. We are delighted to have completed this successful fund-raise which will allow us to dramatically speed our plans for worldwide availability, particularly in the US, Japan, Europe, and other key territories where interest is extremely high."
— Chris Toumazou, CEO and co-founder
Series A
£14.4M

The social investment application raised £14.4m in a Series A convertible offering led by Ventura Capital.

"There is a revolution going on in retail investing. Invstr is here to support that revolution against the new and old dark forces of the financial establishment. We’ve taken the best investment techniques from the rich and made them available to everyone. We help our community members understand their individual investing style and performance, choose stocks that suit their portfolios, share ideas publicly, in groups or private messages, test out their strategies in Fantasy Finance® before they take any real risk and then perform all of their banking and brokerage needs in a single place. Our members are winning the fight. Our real money $100,000 Challenge and Invstr Fantasy League champions are spectacularly outperforming the market and Wall St."
— Kerim Derhalli, Founder and CEO
Series B
$37.0M

The funding round was co-led by MiddleGame Ventures and Ventura Capital to support international growth and product expansion.

"We are thrilled to have the support of world-class investors who bring a highly strategic network to help us continue with the vision (with zero pivots) that Clive [my co-founder] and I started with in 2016."
— Nigel Verdon, CEO and co-founder